Panavance Announces New Discovery that Misetionamide Directly Inhibits Oncogenic Transcription Factor c-MYC
November 19, 2024 07:07 ET
|
Panavance Therapeutics Inc.
New finding builds upon previous confirmation of misetionamide’s direct inhibition of NFkB Direct targeting of these two transcription factors inhibits multiple downstream signaling pathways in...
Panavance Therapeutics Provides Update on Phase 1 Clinical Trial of Misetionamide in Pancreatic Cancer at 2024 Visceral Medicine Congress
October 09, 2024 07:07 ET
|
Panavance Therapeutics Inc.
Misetionamide-gemcitabine combination demonstrates very good safety profile and potential therapeutic benefit in the challenging treatment of pancreatic adenocarcinoma Interim results show ~40% of...
Panavance Therapeutics Announces Foundational Publication of Misetionamide (GP-2250) in Ovarian Cancer in the Journal, Cancer Medicine
August 14, 2024 07:07 ET
|
Panavance Therapeutics Inc.
Misetionamide demonstrated significant single agent activity and synergy with either PARP inhibitors (PARPi) or bevacizumab in ovarian cancer preclinical studiesProfound effects on tumor metabolism,...
Anti-Cancer Drugs Publishes Preclinical Data Demonstrating the Broad Antineoplastic Activity of Panavance’s Misetionamide (GP-2250)
February 01, 2024 07:07 ET
|
Panavance Therapeutics Inc.
Misetionamide showed broad antineoplastic activity in 15 different cancer types including multiple human cancer cell lines with no detrimental effect on normal cells Misetionamide reduces energy...
International Journal of Molecular Sciences Publishes Preclinical Data of Panavance’s Misetionamide (GP-2250) in Melanoma
November 21, 2023 07:07 ET
|
Panavance Therapeutics Inc.
Misetionamide is effective in targeting and killing BRAF-mutated melanoma cells while preserving normal cellsBRAF-mutated melanoma accounts for approximately 50% of all melanomas BERWYN, PA, Nov. ...
Panavance to Present at the BIO Investor Forum
October 05, 2023 07:07 ET
|
Panavance Therapeutics Inc.
BERWYN, PA, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of misetionamide...
Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer
September 12, 2023 07:07 ET
|
Panavance Therapeutics Inc.
Results showed antineoplastic activity in pancreatic tumor cell lines Metabolic and transcriptional findings demonstrate a molecular basis to reduce tumor cell proliferation and induce apoptotic cell...
Panavance Therapeutics to Participate in the Virtual Investor Summer Spotlight Series
July 05, 2023 08:45 ET
|
Panavance Therapeutics Inc.
BERWYN, Pa., July 05, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology...
Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Merkel Cell Carcinoma (MCC)
June 29, 2023 08:05 ET
|
Panavance Therapeutics Inc.
Data indicate that GP-2250 has anti-neoplastic effects in virus-negative MCC cells as evidenced by tumor cell viability, proliferation and migrationGP-2250 demonstrated ability to downregulate protein...
Panavance Therapeutics to Present at the Biotechnology Innovation Organization (BIO) International Convention
May 24, 2023 10:00 ET
|
Panavance Therapeutics Inc.
BERWYN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology...